Patients with pre-existing cardiovascular disease and risk factors are more likely to experience adverse signs associated with the novel corona virus disease-2019 (COVID-19). Additionally, Observational studies have reported an association between underlying cardiovascular diseases (CVD) and SARS COV-2, but this still remains unclear. The aim of this work was to determine the cardiovascular complications of COVID-19 and the cardiovascular co-morbidities related to COVID-19 of 500 Algerian patients hospitalized at Badj Sisters Hospital of Chlef, Algeria before March 2021.
The results demonstrated that RT-PCR is the gold standard technique for diagnosis in combination with CT imaging with rates of (45%) and (51.87%) respectively. COVID-19 can affect all ages, especially people aged 50 years old and over with a rate of (75%), women are more affected than men with a rate of (56%).Although pulmonary manifestations are most often the main focus, SARS COV-2 can also affect the heart and lead to cardiovascular complications. Cardiovascular outcomes reported in COVID-19 infection include cardiac decompensation and renal failure (2.58%), heart failure (5.80%), pulmonary embolism (14.83%) and hypertension (43.87%).
The infection is more intense if the host has cardiovascular comorbidities beforehand. On the other hand, the virus itself can be the direct cause of myocardial and vascular damage. According to the findings, 69% patients demonstrated cardiovascular problems after COVID-19, while 31% represented cardiovascular signs before COVID-19. COVID-19 can cause long hospitalization (5%), paralysis (4%) and death (36%). The impact of SARS COV-2 on the cardiovascular system is doubled.
Keywords: COVID-19, SARS COV-2, Cardiovascular complications, Cardiovascular diseases
